AADI - Aadi Bioscience, Inc.
IEX Last Trade
3.02
0 0%
Share volume: 441,740
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$3.02
-0.58
-0.16%
View ratios
Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | |
---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
Report Date | 2024-05-08 | 2023-08-09 | 2023-11-08 | 2024-11-06 | 2024-05-08 | 2024-08-07 | 2024-11-06 | |
Total revenue | 5.867 M | 6.202 M | 5.959 M | 6.326 M | 5.353 M | 6.179 M | 7.212 M | |
Cost of revenue | 529.000 K | 656.000 K | 697.000 K | 927.000 K | 652.000 K | 778.000 K | 804.000 K | |
Gross profit | 5.338 M | 5.546 M | 5.262 M | 5.399 M | 4.701 M | 5.401 M | 6.408 M | |
3.90% | -5.12% | 2.60% | -12.93% | 14.89% | 18.64% | |||
Operating expenses | 22.163 M | 25.091 M | 23.111 M | 23.113 M | 24.213 M | 20.985 M | 17.183 M | |
Selling general and admin | 11.207 M | 11.776 M | 11.221 M | 10.345 M | 10.620 M | 7.892 M | 7.186 M | |
Research and development | 10.956 M | 13.315 M | 11.890 M | 12.768 M | 13.593 M | 13.093 M | 9.997 M | |
Total expenses | 22.163 M | 25.091 M | 23.111 M | 23.113 M | 24.213 M | 20.985 M | 19.821 M | |
13.21% | -7.89% | 0.01% | 4.76% | -13.33% | -5.55% | |||
Operating income | -16.825 M | -19.545 M | -17.849 M | -17.714 M | -19.512 M | -15.584 M | -13.413 M | |
Ebit | -16.825 M | -19.548 M | -17.849 M | -17.712 M | -19.513 M | -15.586 M | -13.414 M | |
Pretax income | -15.223 M | -17.971 M | -16.302 M | -16.269 M | -18.289 M | -14.583 M | -12.546 M | |
18.05% | -9.29% | -0.20% | 12.42% | -20.26% | -13.97% | |||
Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Net income | -15.223 M | -17.971 M | -16.302 M | -16.269 M | -18.289 M | -14.583 M | -12.546 M | |
-18.05% | 9.29% | 0.20% | -12.42% | 20.26% | 13.97% |